# Pacira BioSciences Mails Letter to Stockholders
Canonical URL: https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders
Ticker: PCRX
Company: Pacira BioSciences
Source: Pacira BioSciences
Published: 2026-05-05 20:20 EST
Original Source URL: https://investor.pacira.com
## Summary

Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results  Reiterates Board’s Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira

## Article Body
Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results  Reiterates Board’s Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira
## Recent Company News
- 2026-06-01 20:50 EST — [Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-highlights-leading-independent-proxy-advisory-firm-iss-recommendation-to-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-28 20:20 EST — [Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees](https://biopharmsignal.com/news/PCRX/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-27 20:20 EST — [Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-reiterating-confidence-in-the-company-s-strategic-direction-and-highly-qualified-nominees) — Source: Pacira BioSciences
- 2026-05-27 12:00 EST — [Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-real-world-study-showing-exparelr-use-was-associated-with-reduced-opioid-use-and-healthcare-costs-in-patients-undergoing-total-shoulder-arthroplasty) — Source: Pacira BioSciences
- 2026-05-26 12:00 EST — [Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy](https://biopharmsignal.com/news/PCRX/pacira-biosciences-sets-the-record-straight-regarding-doma-s-misleading-statements-about-pacira-s-intellectual-property-strategy) — Source: Pacira BioSciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)